Product Description
AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis).
Mechanisms of Action: Angiogenesis Inhibitor,VEGFR Inhibitor
Novel Mechanism: No
Modality: Nondrug
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oragenics
Company Location: TAMPA FL 33634
Company CEO: Kimberly Murphy
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Head and Neck Cancer|Mucositis|Stomatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016-004161-68 | P2 |
Completed |
Mucositis|Head and Neck Cancer |
2020-07-02 |
|
| AG013-ODOM-201 | P2 |
Terminated |
Mucositis|Stomatitis |
2020-03-31 |
24% |
| AG013-ODOM-101 | P1 |
Completed |
Mucositis|Head and Neck Cancer|Stomatitis |
2012-09-01 |